Imunon(IMNN) - 2023 Q4 - Annual Results

Exhibit 99.1 IMUNON Reports 2023 Financial Results and Provides Business Update Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (March 28, 2024) – IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immuno-oncology therapies and next-generation vaccines, today reported financial results for the year ended December 31, 2023. The Company also provided an update on its clinical development programs with IMNN-001, a DNA-based inte ...